{"nctId":"NCT00514514","briefTitle":"Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen","startDateStruct":{"date":"2007-07"},"conditions":["Kidney Transplantation"],"count":802,"armGroups":[{"label":"CNI standard regimen","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Myfortic","Drug: Sandimmun Optoral","Drug: Simulect®"]},{"label":"CNI free regimen","type":"EXPERIMENTAL","interventionNames":["Drug: Everolimus","Drug: Myfortic","Drug: Sandimmun Optoral"]},{"label":"CNI low regimen","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Everolimus","Drug: Sandimmun Optoral"]}],"interventions":[{"name":"Everolimus","otherNames":["Certican"]},{"name":"Myfortic","otherNames":["Enteric Coated Mycophenolate Sodium"]},{"name":"Sandimmun Optoral","otherNames":["Cyclosporine A"]},{"name":"Simulect®","otherNames":["Basiliximab"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria\n\n* Males or females, aged 18 - 70 years\n* Recipients of de novo cadaveric, living unrelated or living related kidney transplants\n* Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at screening, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility.\n* Patients who are willing and able to participate in the study and from whom written informed consent has been obtained.\n\nExclusion criteria\n\n* More than one previous renal transplantation\n* Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any other organ, different from kidney\n* Patients receiving a kidney from a non-heart beating donor\n* Donor age: \\< 5 years or \\> 70 years\n* Graft loss due to immunological reasons in the first year after transplantation (in case of secondary transplantation)\n* Other protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"GFR Via Nankivell Method at Month 12 - CNI-Free vs Standard Regimen","description":"Demonstrate superiority of CNI-Free vs Standard Regimen in GFR using the Nankivell formula (GFR = 6.7 / Scr + BW / 4 - Surea / 2-100 / (height)² + C where where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kilograms, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The calculated GFR is expressed in mL/min per 1.73m², last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate. P-values are not adjusted","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.03","spread":null},{"groupId":"OG001","value":"68.59","spread":null},{"groupId":"OG002","value":"63.08","spread":null}]}]}]},{"type":"SECONDARY","title":"GFR Via Nankivell Formula at Month 12 - All Regimens","description":"Change in GFR using the Nankivell formula (GFR = 6.7 / Scr + BW / 4 - Surea / 2-100 / (height)² + C where where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kilograms, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The calculated GFR is expressed in mL/min per 1.73m², last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.03","spread":null},{"groupId":"OG001","value":"68.59","spread":null},{"groupId":"OG002","value":"63.08","spread":null}]}]}]},{"type":"SECONDARY","title":"GFR at Month 12 Utilizing Modification of Diet in Renal Disease (MDRD) Method","description":"Change in GFR (Modification of Diet in Renal Disease calculated using the -MDRD formulat:\n\nFor men: GFR = 170 × (serum creatinine -0,999)×(age-0,176) x (urea nitrogen -0,17) × (albumin0,318) For women: GFR = 170 × (serum creatinine -0,999) × (age-0,176) × (urea nitrogen -0,17) x (albumin0,318) × 0.762 with urea nitrogen = urea / 2.144. ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.23","spread":null},{"groupId":"OG001","value":"56.36","spread":null},{"groupId":"OG002","value":"50.24","spread":null}]}]}]},{"type":"SECONDARY","title":"GFR at Month 12 Utilizing Cockcroft-Gault Formula","description":"Cockcroft-Gault formula: For men: GFR= ((140-age) × body weight in kg)∕(72 x serum creatinine in mg∕dl)For women: GFR= (0.85×(140-age) × body weight in kg)∕(72 x serum creatinine in mg/dl), ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.18","spread":null},{"groupId":"OG001","value":"64.87","spread":null},{"groupId":"OG002","value":"61.16","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in Serum Creatinine From Month 3 to Month 12","description":"Change in venous blood serum creatinine. Last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.66","spread":null},{"groupId":"OG001","value":"1.58","spread":null},{"groupId":"OG002","value":"1.76","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy Event Data From Baseline 2 (Month 3) to Month 6","description":"Efficacy events were: Biopsy-proven acute rejection (BPAR), graft loss, death, and treatment failure (defined as composite endpoint of BPAR, graft loss, death, loss to follow-up, discontinuation due to lack of efficacy or due to toxicity).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy Event Data Baseline 2 (Month 3) to Month 12","description":"Efficacy events were: Biopsy-proven acute rejection (BPAR), graft loss, death, and treatment failure (defined as composite endpoint of BPAR, graft loss, death, loss to follow-up, discontinuation due to lack of efficacy or due to toxicity).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From BL2 (Month 3) to Month 12 in Cardiovascular Risk (Framingham Score; 10-year Cardiovascular Risk)","description":"The Framingham Score (based on LDL cholesterol level) estimates the coronary heart disease risk (%) of developing one of the following coronary heart diseases: angina pectoris, myocardial infarction, or coronary disease death, over the course of 10 years.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":"8"},{"groupId":"OG001","value":"10.2","spread":"7.4"},{"groupId":"OG002","value":"9.5","spread":"6.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"7.7"},{"groupId":"OG001","value":"8.8","spread":"5.9"},{"groupId":"OG002","value":"9.3","spread":"7.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":"6.8"},{"groupId":"OG001","value":"9.1","spread":"6.4"},{"groupId":"OG002","value":"8.7","spread":"6.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"5.8"},{"groupId":"OG001","value":"0.4","spread":"5.1"},{"groupId":"OG002","value":"-0.7","spread":"5.4"}]}]}]},{"type":"SECONDARY","title":"GFR Calculated Via Nankivell Formula at Month 60","description":"Change in GFR using the Nankivell formula (GFR = 6.7 / Scr + BW / 4 - Surea / 2-100 / (height)² + C where where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kilograms, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The calculated GFR is expressed in mL/min per 1.73m², last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.24","spread":null},{"groupId":"OG001","value":"66.98","spread":null},{"groupId":"OG002","value":"58.74","spread":null}]}]}]},{"type":"SECONDARY","title":"GFR at Month 60 Utilizing Cockcroft-Gault Formula","description":"Cockcroft-Gault formula: For men: GFR= ((140-age) × body weight in kg)∕(72 x serum creatinine in mg∕dl) For women: GFR= (0.85×(140-age) × body weight in kg)∕(72 x serum creatinine in mg/dl), ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.92","spread":null},{"groupId":"OG001","value":"61.6","spread":null},{"groupId":"OG002","value":"52.91","spread":null}]}]}]},{"type":"SECONDARY","title":"GFR at Month 60 Utilizing Modification of Diet in Renal Disease (MDRD) Method","description":"Change in GFR (Modification of Diet in Renal Disease calculated using the -MDRD formulat:\n\nFor men: GFR = 170 × (serum creatinine -0,999)×(age-0,176) x (urea nitrogen -0,17) × (albumin0,318) For women: GFR = 170 × (serum creatinine -0,999) × (age-0,176) × (urea nitrogen -0,17) x (albumin0,318) × 0.762 with urea nitrogen = urea / 2.144. ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.56","spread":null},{"groupId":"OG001","value":"53.41","spread":null},{"groupId":"OG002","value":"44.79","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in Serum Creatinine From Month 3 to Month 60","description":"Change in venous blood serum creatinine. Last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.94","spread":null},{"groupId":"OG001","value":"1.69","spread":null},{"groupId":"OG002","value":"2.01","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy Event Data After Month 12 to Month 60","description":"Efficacy events were: Biopsy-proven acute rejection (BPAR), graft loss, death, and treatment failure (defined as composite endpoint of BPAR, graft loss, death, loss to follow-up, discontinuation due to lack of efficacy or due to toxicity).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"36","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":87,"n":165},"commonTop":["NASOPHARYNGITIS","URINARY TRACT INFECTION","LEUKOPENIA","DIARRHOEA","OEDEMA PERIPHERAL"]}}}